Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours Β· Estimated delivery Aug 26 - Aug 31
First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting
What Clinicians Should Discuss: Patient History: Thoroughly review a patient's history, including previous weight loss attempts, to support insurance applications [5e94]
With Zepbound, 89.3% received at least one dose of the 15 mg dose and with Wegovy 92.8% received at least one dose of the 2.4 mg dose
A short track to metabolic health Wegovy and Ozempic reinvigorate the colonic brake downstream of food and microbes with molecules similar to GLP-1
The findings, published in BMJ Open Diabetes Research & Care , represent the first direct comparison between GLP-1s and metformin
